The FDA issued draft guidance on oncology clinical trials, taking the first steps toward formalizing a position that it's ...

These extra doses will bring more highly specialised work making these novel molecules to contract manufacturing ...

KEY TAKEAWAYS Pfizer said this weekend that a drug aimed at helping cancer patients losing appetite and muscle mass showed ...

Ponsegromab reached a clinically meaningful 5.6% mean weight increase at the high dose level in patients with cancer cachexia ...

On August 22, Moderna announced that FDA approved its supplemental Biologics License Application ... we saw more than 600,000 hospitalizations due to COVID in the U.S.” On the same day, Pfizer and ...

KP.2-adapted COVID-19 vaccine received FDA approval. Manufacturing Optimization Program aims to deliver $1.5b in savings by ...

Pfizer is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug ...

Pfizer Inc. (NYSE: PFE) experienced a notable uptick in its stock price during Monday’s trading session, climbing by +2.12% to reach $29.89 at 11:10 AM EDT. This positive movement comes in the wake of ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced its Phase 2 study ... iv Despite its severity, there are no FDA-approved treatments for cachexia. iii About Ponsegromab Ponsegromab ...

Pfizer Inc. (PFE) announced longer-term follow-up results from the Phase 2 single-arm PHAROS clinical trial evaluating the efficacy ...

Pfizer's recent financial performance shows 14% YoY operational growth excluding COVID sales. Check out more on PFE stock ...

A drug that could reduce the risk of death in cancer patients is showing good promise during its second phase of clinical ...